Nile Therapeutics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference
SAN FRANCISCO, Aug. 27 /PRNewswire-FirstCall/ — Nile Therapeutics, Inc., , today announced that Peter Strumph, Chief Executive Officer of Nile, will present at the NewsMakers in the Biotech Industry conference on Thursday, September 4, at 1:30 p.m. EDT at the Millennium Broadway Hotel in New York City. Mr. Strumph will provide a company overview and update on the status of Nile’s current clinical development programs.
The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Nile’s website at http://www.nilethera.com/. The webcast will be archived for 90 days.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company’s strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com/.
Contact: Daron Evans Chief Financial Officer Nile Therapeutics, Inc. 415-875-7880 email@example.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile’s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the “Risk Factors” section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Nile Therapeutics, Inc.
CONTACT: Daron Evans, Chief Financial Officer, Nile Therapeutics, Inc.,+1-415-875-7880, firstname.lastname@example.org
Web site: http://www.nilethera.com/